Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Summary

This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or without trametinib may work better in treating patients with stage IV colorectal cancer.

Timeline

Start

2017-12-29

Primary completion

2027-01-31

Completion

2027-01-31

Drugs

Indications